Jove
Visualize
Contact Us

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

718
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
718
Modern Molecular Taxonomy01:29

Modern Molecular Taxonomy

305
Advancements in molecular biology have revolutionized the identification and characterization of bacteria, with multiple methods leveraging DNA sequencing for enhanced precision. As sequencing technologies improve and costs decline, these approaches are increasingly used in clinical, environmental, and evolutionary studies.Multilocus Sequence Typing (MLST) examines several housekeeping genes, essential chromosomal genes encoding cellular functions, to distinguish strains. Approximately...
305
MALDI-TOF Mass Spectrometry01:19

MALDI-TOF Mass Spectrometry

5.9K
Mass spectrometry is a powerful characterization technique that can identify and separate a wide variety of compounds ranging from chemical to biological entities, based on their mass-to-charge ratio (m/z). The instruments that allow this detection, known as mass spectrometers, have three components: an ion source, a mass analyzer, and a detector. These spectrometers differ based on the nature of their ion source and analyzers.
Matrix-assisted laser desorption ionization (MALDI) is a commonly...
5.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[«Criminal» local anesthesia in dentistry: a deliberate risk or a game without rules?]

Stomatologiia·2021
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Oct 24, 2025

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE
07:10

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE

Published on: April 21, 2019

16.6K

New technologies in molecular allergodiagnostics.

M A Mokronosova1, O I Filimonova2, Tatyana M Zheltikova1

  • 1Mechnikov Research Institute of Vaccines and Serum.

Klinicheskaia Laboratornaia Diagnostika
|August 13, 2021
PubMed
Summary
This summary is machine-generated.

This article reviews the ALEX2 test system, a new tool for identifying allergy triggers. By testing for hundreds of allergens at once, it helps doctors pinpoint specific causes of allergic reactions and plan safer, more effective treatments for patients.

Keywords:
allergen detection assayallergen moleculesmolecular allergologymultiplex test systemsrecombinant and/or purified natural allergen componentsmultiplex immunoassayIgE antibodiesallergen-specific immunotherapyclinical validation

Frequently Asked Questions

More Related Videos

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

3.7K
Murine Model of Allergen Induced Asthma
08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

40.7K

Related Experiment Videos

Last Updated: Oct 24, 2025

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE
07:10

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE

Published on: April 21, 2019

16.6K
Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

3.7K
Murine Model of Allergen Induced Asthma
08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

40.7K

Area of Science:

  • Molecular allergodiagnostics research within clinical immunology
  • Diagnostic technology assessment in allergy medicine

Background:

Current diagnostic tools often struggle to differentiate between true sensitization and non-specific binding reactions. This limitation creates uncertainty in identifying the precise triggers for patient symptoms. Prior research has shown that cross-reactive carbohydrate determinants frequently interfere with standard testing accuracy. That uncertainty drove the development of more advanced multiplex platforms. No prior work had fully resolved the challenges of simultaneous detection for both extracts and molecules. This gap motivated the introduction of the ALEX2 system for clinical use. Scientists sought to improve upon existing solid-phase enzyme immunoassays. The field required a more comprehensive approach to mapping complex sensitization profiles.

Purpose Of The Study:

The aim of this article is to present the characteristics and clinical utility of the ALEX2 test system. This technology addresses the need for simultaneous detection of total and specific IgE antibodies. Researchers sought to resolve the limitations associated with traditional diagnostic methods in allergy medicine. The study explains how the immune allergy chip facilitates component-resolved diagnostics for complex patient cases. It explores the motivation for integrating both extracts and purified molecules into a single assay. The authors investigate how this system improves the identification of dominant sensitizing factors. They examine the potential for this tool to refine treatment indications and immunotherapy effectiveness. The work provides a detailed overview of the system's role in predicting patient outcomes and anaphylaxis risks.

Main Methods:

The review approach evaluates the technical specifications of the novel immune allergy chip platform. Researchers examined the solid-phase enzyme immunoassay protocol used for detecting specific antibodies. The analysis focused on the integration of 120 extracts and 180 molecules within a single matrix. Investigators compared these performance metrics against the ImmunoCAP macroarray system. The study design involved verifying the inhibition method for cross-reactive carbohydrate determinants. Experts assessed the reliability of the multiplex matrix in clinical settings. The investigation included a validation phase conducted by the Institute of Clinical and Laboratory Standards. This methodology provided a comprehensive overview of the diagnostic capabilities offered by the new technology.

Main Results:

Key findings from the literature demonstrate that the ALEX2 system provides results comparable to the ImmunoCAP test platform. The technology successfully identifies sensitization to 300 distinct targets through a single assay. The authors report that the inclusion of unique molecules improves the resolution of complex allergy profiles. Evidence shows that the inhibition of cross-reactive carbohydrate determinants effectively minimizes non-specific binding events. The system allows for the detection of dominant sensitizing factors in patients with polyvalent sensitization. Data indicate that the platform provides actionable insights for assessing anaphylaxis risks. The findings confirm that the matrix supports the determination of indications for allergen-specific immunotherapy. Results suggest that the technology enhances the ability to predict future treatment paths for patients.

Conclusions:

The authors propose that this multiplex platform improves the precision of component-resolved allergy diagnostics. Synthesis and implications suggest that identifying dominant sensitizing factors guides better clinical decision-making. Researchers indicate that the system helps clinicians determine appropriate indications for allergen-specific immunotherapy. The evidence implies that practitioners can more accurately assess anaphylaxis risks using these detailed profiles. Findings suggest that the inhibition of cross-reactive carbohydrate determinants reduces non-specific binding interference. The review highlights that the technology supports effective management of both mono- and polyvalent sensitization cases. Authors conclude that the platform assists in predicting long-term treatment strategies for allergic patients. This synthesis confirms the utility of advanced molecular tools in modern clinical allergy practice.

The researchers propose that the system utilizes a solid-phase enzyme immunoassay to simultaneously detect total IgE and specific IgE antibodies against 300 distinct targets. This mechanism contrasts with traditional single-allergen tests, which require separate assays for each individual substance.

The platform incorporates a macroscopic multiplex matrix, known as an immune allergy chip, where allergen extracts and molecules are attached to nanoparticles. This differs from the ImmunoCAP system, which typically relies on different substrate configurations for its diagnostic measurements.

Authors state that inhibiting cross-reactive carbohydrate determinants is necessary to prevent non-specific binding of IgE antibodies. This technical step is required to ensure that the results reflect true sensitization rather than false-positive signals often seen in other assays.

The system utilizes a combination of 120 allergen extracts and 180 purified molecules to provide a comprehensive profile. This data type allows clinicians to distinguish between broad extract-based reactions and specific molecular sensitivities that are not possible with simpler diagnostic panels.

The researchers report that the ALEX2 system shows comparable results to the ImmunoCAP macroarray test. This measurement confirms that the new technology maintains diagnostic consistency when evaluated against the established standard currently used in clinical laboratories.

The authors propose that the test results influence the selection of allergen-specific immunotherapy. By identifying the dominant sensitizing factor, clinicians can better predict patient outcomes and tailor treatment tactics compared to traditional methods that lack component-level resolution.